Expected to complete its primary endpoint around February 2027, the trial reflects a broader strategic shift in the obesity market, where alternative delivery methods like patches, oral pills, and subcutaneous implants are becoming key battlegrounds for competitive differentiation ahead of eventual losses of exclusivity
Jiang S, Xie S, Lv D, Wang P, He H, Zhang T, Zhou Y, Lin Q, Zhou H, Jiang J, Nie J, Hou F, Chen Y
The most common are mild digestive effects like nausea, which usually ease as your body adjusts
extremely low-fat diets paradoxically increase stone risk
J Hematol Oncol 10:60 Ou C, Sun Z, Li X, Ren W, Qin Z, Zhang X et al (2017) MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer